Skip to main content

Advertisement

SpringerLink
Log in

Can cetuximab affect paraneoplastic myopathy?

  • Case Report
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 15 February 2009

Abstract

Cetuximab given concurrently with chemotherapy has shown survival benefit for patients with metastatic colon cancer. We report a case of a patient with metastatic colon cancer who developed paraneoplastic necrotizing myopathy that possibly responded to cetuximab despite lack of improvement of the underlying cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345. doi:10.1056/NEJMoa033025

    Article  PubMed  CAS  Google Scholar 

  2. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A (1998) Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50(3):764–767

    PubMed  CAS  Google Scholar 

  3. Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM (2007) Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 17(5):404–408. doi:10.1016/j.nmd.2007.01.004

    Article  PubMed  CAS  Google Scholar 

  4. Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24:487–499. doi:10.1007/s10555-005-6192-2

    Article  PubMed  CAS  Google Scholar 

  5. Kim J, Lee CK, Park HJ, Kim HJ, So HH, Lee KS, Lee HM, Roh HY, Choi WS, Park TK, Kim B (2006) Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J Pharmacol Sci 101(2):135–143. doi:10.1254/jphs.FP0060021

    Article  PubMed  CAS  Google Scholar 

  6. Florian JA, Watts SW (1999) Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 276(3 Pt 2):H976–H983

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Oncology Department, Metropolitan Hospital, Ethn. Makariou 9, N. Faliro, 18547, Athens, Greece

    Eleni Galani, Christos Christodoulou, George Klouvas & Dimostenis Skarlos

  2. Egenition Hospital, Neurological Department, University of Athens, Vasilissis Sofias Av. 72, PC 11528, Athens, Greece

    Anastasios Bonakis

  3. Department of Histopathology, Red Cross Hospital, Erithrou Staurou 1, Athens, Greece

    Drougou Angeliki

Authors
  1. Eleni Galani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anastasios Bonakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christos Christodoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Klouvas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Drougou Angeliki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dimostenis Skarlos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasios Bonakis.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11060-009-9808-5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galani, E., Bonakis, A., Christodoulou, C. et al. Can cetuximab affect paraneoplastic myopathy?. J Neurooncol 93, 437–438 (2009). https://doi.org/10.1007/s11060-009-9795-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9795-6

Keywords

Search

Navigation